Form 4 for ANTX AN2 Therapeutics, Inc.
Accepted 2025-01-07 00:00:00 ET · period of report 2025-01-03 · accession 0000950170-25-003157 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-07 | 2025-01-03 | ANTX | Chanda Sanjay | Chief Development Off | S - Sale | $1.34 | -2,957 | 29.8K | -9% | -$3,962 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-03 | S | D | 2,957 | $1.34 | 29,824 | D | — | — | (F1) Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2025. (F2) Includes 20,625 RSUs which vest as follows: 1/3rd of the RSUs vest annually over three years from January 1, 2025, subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date. (F3) Includes 2,224 shares purchased on March 31, 2024 under the Issuer's Employee Stock Purchase Plan ("ESPP") and 2,322 shares purchased on September 30, 2024 under ESPP in transactions exempt from reporting under Section 16(b)3. |